Treating IgG4-related disease with mild steroid starts
Part of Immune system & allergy clinical trials.
This trial is studying treatment plans for people with IgG4-related disease that affects a surface (superficial) organ area. It focuses on people who are newly diagnosed or have come back and who need to start or continue steroid medicine at a low dose.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been told you meet IgG4-related disease diagnosis rules (per ACR/EULAR 2019).
- Your disease is newly diagnosed or has come back (relapsed).
- You need to start or continue steroid (glucocorticoid) treatment.
- The steroid dose you started is less than 10 mg per day (or it is being continued from that low starting point).
- You do not have another autoimmune disease instead of IgG4-related disease.
- You are not currently pregnant or breastfeeding, and you do not have active infections like HIV, hepatitis B/C, or tuberculosis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine called telitacicept combined with low-dose steroids for people with hard-to-treat myasthenia gravis. The goal is to see if this combination can better control symptoms that haven't improved with standard treatments.
This trial tests a short course of steroids combined with mycophenolate mofetil (MMF) for people with active IgG4-related disease who have not been treated before or whose disease came back after stopping treatment. The goal is to see if this combination helps control the disease better.
This trial tests if lenalidomide, taken as a pill, can help prevent IgG4-related disease from coming back (relapsing) in people who are already in remission on low-dose steroids.
This trial tests whether a special type of immune cell therapy (CAR-T) can help people whose IgG4-related disease persists despite steroids or rituximab. It focuses on those with inflammation in two or more major organs.
This study tests a drug called lenalidomide to see if it can help control active IgG4-related disease, a condition that causes inflammation and swelling in organs. The drug is taken by mouth, and the study compares it to a placebo (a pill with no medicine).
This is a study that follows people diagnosed with IgG4-related disease to better understand the condition. It may help researchers confirm diagnoses and learn how the disease affects different organs over time.
Hear when a new Autoimmune Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.